TY - JOUR
T1 - Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
AU - Rossi, Ernesto
AU - Maiorano, Brigida Anna
AU - Pagliara, Monica Maria
AU - Sammarco, Maria Grazia
AU - Dosa, Tommaso
AU - Martini, Maurizio
AU - Rindi, Guido
AU - Bria, Emilio
AU - Blasi, Maria Antonietta
AU - Tortora, Giampaolo
AU - Schinzari, Giovanni
PY - 2019
Y1 - 2019
N2 - Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
AB - Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
U2 - 10.3389/fonc.2019.00232
DO - 10.3389/fonc.2019.00232
M3 - Article
C2 - 31024839
VL - 9
SP - 232
JO - Frontiers in Oncology
JF - Frontiers in Oncology
SN - 2234-943X
ER -